Toliman P, Badman S G, Gabuzzi J, Silim S, Forereme L, Kumbia A, Kombuk B, Kombati Z, Allan J, Munnull G, Ryan C, Vallely L M, Kelly-Hanku A, Wand H, Mola G D L, Guy R, Siba P, Kaldor J M, Tabrizi S N, Vallely A J
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
The Kirby Institute, UNSW Australia, Sydney, Australia.
J Clin Microbiol. 2016 Jul;54(7):1734-1737. doi: 10.1128/JCM.00529-16. Epub 2016 Apr 13.
The World Health Organization has recommended that testing for high-risk human papillomavirus (HPV) (hrHPV) infection be incorporated into cervical screening programs in all settings worldwide. In many high-burden, low-income countries, it will not be feasible to achieve high cervical screening coverage using hrHPV assays that require clinician-collected samples. We conducted the first evaluation of self-collected vaginal specimens compared with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. Women aged 30 to 54 years attending two well-woman clinics in Papua New Guinea were invited to participate and provided self-collected vaginal and clinician-collected cervical cytobrush specimens. Both specimen types were tested at the point of care by using the Xpert HPV test. Women were given their cervical test result the same day. Those with a positive hrHPV test and positive examination upon visual inspection of the cervix with acetic acid were offered same-day cervical cryotherapy. A total of 1,005 women were enrolled, with 124 (12.3%; 95% confidence interval [CI], 10.3%, 14.4%) being positive for any hrHPV infection. There was a 99.4% overall percent agreement (OPA) between vaginal and cervical tests for HPV-16 (95% CI, 98.9%, 99.9%), a 98.5% OPA for HPV-18/45 (95% CI, 97.7%, 99.3%), a 94.4% OPA for other hrHPV infections (95% CI, 92.9%, 95.9%), and a 93.4% OPA for all hrHPV types combined (95% CI, 91.8%, 95.0%). Self-collected vaginal specimens had excellent agreement with clinician-collected cervical specimens for the detection of hrHPV infection using the Xpert HPV test. This approach provides for the first time an opportunity to incorporate point-of-care hrHPV testing into clinical cervical screening algorithms in high-burden, low-income settings.
世界卫生组织建议,在全球所有地区的宫颈癌筛查项目中纳入高危型人乳头瘤病毒(hrHPV)感染检测。在许多高负担、低收入国家,使用需要临床医生采集样本的hrHPV检测方法来实现高宫颈癌筛查覆盖率是不可行的。我们开展了首次评估,比较自我采集的阴道标本与临床医生采集的宫颈标本,使用Xpert HPV检测来检测hrHPV感染情况。邀请了在巴布亚新几内亚两家妇女健康诊所就诊的30至54岁女性参与,并提供自我采集的阴道标本和临床医生采集的宫颈细胞刷标本。两种标本类型均在现场使用Xpert HPV检测进行检测。女性在同一天得到她们的宫颈检测结果。hrHPV检测呈阳性且在宫颈醋酸目视检查时检查呈阳性的女性接受了当天的宫颈冷冻治疗。总共招募了1005名女性,其中124名(12.3%;95%置信区间[CI],10.3%,14.4%)任何hrHPV感染呈阳性。HPV-16的阴道和宫颈检测总体一致性百分比(OPA)为99.4%(95%CI,98.9%,99.9%),HPV-18/45的OPA为98.5%(95%CI,97.7%,99.3%),其他hrHPV感染的OPA为94.4%(95%CI,92.9%,95.9%),所有hrHPV类型合并的OPA为93.4%(95%CI,91.8%,95.0%)。使用Xpert HPV检测,自我采集的阴道标本与临床医生采集的宫颈标本在检测hrHPV感染方面具有极好的一致性。这种方法首次为在高负担、低收入地区将现场hrHPV检测纳入临床宫颈癌筛查算法提供了机会。